title: Preventing hospitalizations for respiratory syncytial virus infection.
abstract: Respiratory syncytial virus infection is the leading cause of lower respiratory tract infections in young children. Palivizumab has minimal impact on RSV hospitilization rates as it is only practical to offer it to the highest risk groups. The present statement reviews the published literature and provides updated recommendations regarding palivizumab use in children in Canada.
authors.forename: Joan L
authors.initials: JL
authors.lastname: Robinson
authors.forename: Nicole
authors.initials: N
authors.lastname: Le Saux
keywords: At-risk infants; Chronic lung disease; Congenital heart disease; Palivizumab; Prematurity; Prophylaxis; RSV